KEYNOTE-355
Regimen
- Experimental
- Pembrolizumab 200 mg Q3W + investigator's choice chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine/carboplatin).
- Control
- Placebo + identical chemotherapy.
Population
Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer, at least 6 months since prior (neo)adjuvant chemotherapy.
Key finding
KEYNOTE-355 established pembrolizumab + chemotherapy as standard 1L in PD-L1 CPS>=10 metastatic TNBC (NCCN category 1; FDA approved November 2020). Benefit restricted to PD-L1-high tumors, confirmed OS gain.
Source: PMID 33278935
Timeline
- Publication: 2020 Dec 5
Guideline citations
- NCCN BREAST